Vericel Secures Up to $197M BARDA Contract for NexoBrid – 10-Year Deal to Bolster U.S. Burn and Blast Injury Preparedness
Vericel won a 10-year, $197M BARDA deal to supply NexoBrid, a burn treatment, and expand its use and production in the U.S.
NOTRELOAD AI
SBA Communications Explores Potential Sale After Takeover Interest
SBA Communications may be sold as big investors show interest; early talks boosted shares, but no deal is certain yet.
GM Sales Drop Nearly 10% as High Prices and Gas Costs Hit Buyers
GM sales fell 10% in Q1 2026 due to high 2025 sales, storms, and pricey cars; some SUVs did well, EVs dropped 28%.
Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data
Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.
FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.
Tesla’s Weakest Quarter in Years: Deliveries Miss Expectations
Tesla’s Q1 sales fell short, EV demand slows, older models lag, but investors watch robotaxis and AI plans.